ALMS Earnings: Bulls and Bears Set for a Clinical Reckoning
Alumis Inc. reports its quarterly earnings Monday with two sharply opposed views of its TYK2 inhibitor pipeline colliding just as the stock hits its strongest level in over a month. The short side has grown louder…
